BioSpace News Archive

Dermira, Inc. announced that company management will participate in the 2019 Cantor Global Healthcare Conference taking place October 2-4, 2019 in New York, NY.

TSO3 Inc. announced that the Superior Court of Québec issued a final order approving the previously-announced statutory plan of arrangement under the Business Corporations Act pursuant to which a wholly-owned subsidiary of Stryker Corporation will acquire all of the issued and outstanding common shares of the Company for CAD$0.43 per share in cash.

United Biologics, Inc., a global leader in silicone vasculature, announced the appointment of John Barnhill as President and General Manager.

Including Cefiderocol Phase III APEKS-NP Trial as Late-breaker Oral Presentation

$3 Million Gift Helps Launch Center to Support Patient Care, Psychosocial Initiatives, Research and Recruitment

TWILIGHT Study Fails to Answer Key Scientific Question Regarding Most Efficacious Treatment Post-PCI

Approval represents first and only FDA-approved biologic indicated for newly diagnosed patients who are eligible for a stem cell transplant

New data from TWILIGHT, a Phase IV independent trial, showed that in patients at high-bleeding risk who underwent PCI and completed three months of dual antiplatelet therapy, BRILINTA monotherapy reduced the risk of BARC type 2, 3 or 5 bleeding compared to BRILINTA plus low-dose aspirin after 12 months.

Enables the Clinical, Economic, and Patient Benefits Associated with Radial Artery Access

Company to receive up to $8 million for its Kv7 platform as part of federal program to apply scientific solutions to reverse the national opioid crisis